QZQiyun Zhu

Qiyun Zhu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Qiyun Zhu has a total of 170 co-authors. Here are the top co-authors by number of shared publications:

  • Yanhong Ji

    State Key Laboratory for Animal Disease Control and Prevention, College of Veterinary Medicine, Lanzhou University, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou, 730000, China

    15 shared publications
  • Zhengxiang Wang

    State Key Laboratory of Veterinary Etiological Biology, Lanzhou Veterinary Research Institute, CAAS, 1 Xujiaping, Lanzhou 730046, China

    13 shared publications
  • Shuai Xu

    State Key Laboratory for Animal Disease Control and Prevention, College of Veterinary Medicine, Lanzhou University, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences

    12 shared publications
  • Yane Jia

    State Key Laboratory of Veterinary Etiological Biology, Lanzhou Veterinary Research Institute, CAAS, 1 Xujiaping, Lanzhou 730046, China

    12 shared publications
  • Qian Wang

    College of Veterinary Medicine, Gansu Agricultural University, Lanzhou, China

    11 shared publications
  • Shuai Xu

    State Key Laboratory of Animal Disease Control and Prevention, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou, China

    10 shared publications

Latest Publications

  • Open Access

    mRNA-LNP delivery of a homo-tandem nanobody protects goslings from novel goose astrovirus infection

    by Dan Wang, Xianyu Shao, Yi Ai, Lebin Han, Huarui Liu, Xinlong Zhang, Ang Lin, Qiyun Zhu

    Novel goose astrovirus (nGAstV) infection causes visceral gout and high mortality in goslings, but at present, there are no effective vaccines or antiviral agents. Here, we identified a neutralizing nanobody (Nb60) targeting the spike (P2) protein of nGAstV capable of inhibiting viral replication by blocking both viral attachment and entry. For effective in vivo delivery, we designed an mRNA-encoded homo-tandem nanobody (3×Nb60) flanked by an Anser interleukin-2 (IL-2) signal peptide and Anser untranslated regions that exhibited an approximately twofold improvement in neutralization potency compared to the mRNA-encoded Nb60 monomer. The mRNA encoding nanobody was encapsulated with lipid nanoparticles (LNPs) to prolong its half-life in serum by approximately 48 h. In a gosling infection model, the 3×Nb60 mRNA-LNP (2 mg/kg) produced 100% survival for both prophylaxis and therapy, significantly reduced viral shedding and viral loads in tissues, attenuated hepatic and renal pathology, and restored serum uric acid, alanine aminotransferase, and aspartate aminotransferase levels to close to the baseline values. Epitope mapping revealed that Nb60 recognizes a critical conformational epitope on the P2 protein, with residues 529R and 553G being essential for binding. The findings establish an mRNA-encoded nanobody platform as a promising strategy for prophylaxis and therapy in the early stages of nGAstV infection. IMPORTANCE: Novel goose astrovirus (nGAstV) has caused widespread outbreaks of visceral gout in goslings across China since 2017, leading to substantial economic losses in the poultry industry. The disease predominantly affects goslings under 3 weeks of age, and the short disease course limits the utility of conventional vaccines. This study establishes an mRNA-encoded nanobody (Nb) platform in which avian-specific regulatory elements, including an Anser IL-2 signal peptide and an Anser globin untranslated region, enable efficient expression of a neutralizing Nb60 in avian cells. A homo-tandem design (3×Nb60) further prolongs the in vivo half-life, improves antiviral potency, and provides complete protection in goslings. By offering a species-matched delivery framework, this platform provides a rapid-response strategy for emerging avian viral diseases and may also shed light on the development of mRNA-encoded antibody therapeutics against human enteric viruses.

  • Glycolytic enzyme PGK1 restricts viral replication via a glycolysis-independent mechanism

    by Yanli Wei, Shuai Xu, Qian Wang, Yinghong Jin, Jucai Ding, Jiaxin Huang, Lu Han, Caoqi Lei, Jun Xia, Qiyun Zhu, et al.

    The development of effective and broad-spectrum antiviral therapies remains an urgent need. Identifying key host factors that participate in the viral life cycle may provide novel targets for the development of antiviral strategies. Herein, through tandem affinity purification-mass spectrometry and siRNA screening, we identified that a glycolytic enzyme, phosphoglycerate kinase 1 (PGK1), exerts a restrictive effect on the replication of influenza A virus (IAV). Furthermore, PGK1 was found to inhibit the replication of multiple other viruses, including Sendai virus, vesicular stomatitis virus, and herpes simplex virus 1. Although PGK1 is a glycolytic enzyme, its antiviral effect is independent of glycolysis and instead relies on decreasing the stability of multiple viral proteins. The kinase activity of PGK1 was essential for reducing the stability of viral proteins, but PGK1 did not directly catalyze their phosphorylation. Phosphoproteomic analysis revealed that the heat shock protein HSP90AA1 is a critical substrate phosphorylated by PGK1. By directly catalyzing the serine phosphorylation of HSP90AA1, PGK1 decreased the molecular chaperone activity and mediated the ubiquitin-proteasome degradation of HSP90AA1, leading to the instability of viral proteins and reduced viral replication. Interestingly, the IAV nucleoprotein (NP) competitively interacted with PGK1 to disrupt the PGK1-HSP90AA1 association, thereby antagonizing the antiviral effect of PGK1. Collectively, these findings suggest that PGK1 is a novel restrictive factor that inhibits viral replication by targeting the molecular chaperone HSP90AA1. Additionally, the intermolecular interaction between PGK1 and HSP90AA1 may provide a promising target for the development of broad-spectrum antiviral drugs.

  • Open Access

    A one-tube RT-RPA–CRISPR/Cas12a system for zoonotic virus detection

    by Dongqi Ling, Pengfei Yang, Nana Gong, Jinjin Zhang, Yingying Du, Shuai Xu, Qiyun Zhu

    Zoonotic viruses, such as the Nipah virus (NiV), Hendra virus (HeV), Rift Valley fever virus (RVFV), and Crimean–Congo hemorrhagic fever virus (CCHFV), pose substantial threats to global public health. Early and precise detection of these pathogens is crucial for their effective prevention and control; however, there are limitations to field applications of conventional diagnostic approaches which rely on large equipment or complex operations. In this study, we developed a rapid one-tube visual detection assay for four viruses, respectively, by integrating reverse transcription recombinase polymerase amplification (RT-RPA) with CRISPR/Cas12a technology. The system incorporates highly specific CRISPR RNAs that target conserved regions of the nucleocapsid (N) genes from the 4 viruses under isothermal conditions at 39 °C. To simulate clinical conditions, we constructed recombinant vesicular stomatitis viruses expressing the N gene (rVSV-N) of NiV, HeV, RVFV, and CCHFV, respectively. Results indicated that the RT-RPA–CRISPR/Cas12a system could visually detect rVSV-N in lung samples from infected mice, with a detection limit of 1 copy/μL of viral RNA, within 40 min in a one-tube system at 39 °C isothermally. Our highly sensitive, specific, and visual one-tube detection system for NiV, HeV, RVFV, and CCHFV offers significant potential for early and accurate on-site detection of these viruses.


  • Open Access

    A ferritin-based mosaic-like nanovaccine elicits effective cross-protection against H1N1 and H3N2 swine influenza viruses

    by Lebin Han, Dan Wang, Jinjin Zhang, Xiangkun Wang, Yingying Du, Qin Yang, Guanggang Qu, Yihong Xiao, Qiyun Zhu

    Swine influenza viruses (SIVs), particularly the H1N1 and H3N2 subtypes, pose ongoing threats to the swine industry and global public health. Current commercial vaccines generally provide limited cross-protection against heterologous viruses due to the frequent antigenic drift and shift in SIVs, highlighting the need for broad-spectrum vaccines. Self-assembling nanoparticles (NPs) can elicit strong and broad immune responses, representing a promising platform for the development of broad-spectrum nanovaccines. In this study, two newly-screened conserved epitopes (H1-3 and H1-5) and (H3-1 and H3-3) in hemagglutinin (HA) of the H1 and H3 subtypes, along with a highly conservative matrix protein 2 ectodomain (M2e), were displayed on ferritin NP in cocktail and mosaic forms, respectively, and were designated MHF-cocktail (MHFc) and MHF-mosaic (MHFm) nanovaccines. Under a prime-boost immunization strategy in a mouse model, the MHFm nanovaccine induced a higher antigen-specific IgG mediated antibody dependent cellular cytotoxicity (ADCC) than the MHFc nanovaccine, and significantly enhanced antigen-specific multifunctional CD4⁺ and CD8⁺ T cell responses as well as cytotoxic T-cell activity. Enzyme-linked immunosorbent spot proliferation assays indicated that splenic lymphocytes generated following vaccination with the MHFm nanovaccine exhibited enhanced proliferative capacity and secreted higher levels of interleukin-4 (IL-4) and interferon-γ (IFN-γ) compared with those from the MHFc nanovaccine. In mice, MHFm nanovaccine provided complete cross-protection against lethal H1N1 and H3N2 SIV challenge, while MHFc nanovaccine offered partial cross-protection. This study provides a potential strategy for designing and developing cross-protective vaccines against H1N1 and H3N2 SIVs.

  • Influenza a virus NS2 suppresses NFKB/NF-κB signaling to facilitate viral replication by mediating the autophagic-degradation of IKBKG/NEMO

    by Bo Zhang, Lebin Han, Chenying Cui, Jiaxin Huang, Qiyun Zhu, Caoqi Lei, Shuai Xu

    Influenza A virus (IAV) is a leading cause of severe respiratory disease in humans and animals [1,2]. The most devastating event was the H1N1 pandemic of 1918, which caused 40 million deaths [3]. C...


  • Open Access

    Tyrosine kinase LYN restricts the replication and virulence of influenza A virus by directly phosphorylating viral nucleoprotein

    by Junwen Liu, Jiaxin Huang, Qian Wang, Yanli Wei, Lebin Han, Xin Li, Caoqi Lei, Guohua Deng, Hualan Chen, Qiyun Zhu, et al.

    The continuous antigenic shift and drift of influenza A virus (IAV) result in the emergence of novel strains and drug resistance. Accordingly, it is urgent to develop novel antiviral drugs that target host factors. Here, we revealed that tyrosine kinase LYN (Lck/Yes-related novel protein tyrosine kinase) interacts directly with nucleoprotein (NP) and reduces the replication and virulence of IAV in vitro and in vivo , in a kinase-dependent manner. By directly catalyzing the tyrosine phosphorylation of NP at Y10/40/97 sites, LYN impairs the interaction of NP with viral RNA and polymerase proteins, as well as the oligomerization of NP, and thus negatively modulates the assembly of the viral ribonucleoprotein complex. The NP Y10/40/97F mutation significantly increases the pathogenicity of IAV in mice. Furthermore, the LYN-specific agonist MLR-1023 showed promising therapeutic effects against IAV. Collectively, our findings suggest that LYN is a novel host kinase restricting IAV replication, and a promising target for anti-influenza drug development. IMPORTANCE: The nucleoprotein (NP) of influenza A virus (IAV) is a highly conserved, multifunctional, and the most abundant viral protein in infected cells, which makes NP a promising target for the development of anti-influenza drugs. Phosphorylation plays a crucial role in the stability and functionality of NP. However, few kinases have been identified that directly phosphorylate NP. In this study, LYN (Lck/Yes-related novel protein tyrosine kinase) was identified as a novel kinase that directly catalyzes the tyrosine phosphorylation of IAV NP and thus restricts the replication and virulence of IAV. The LYN-specific agonist MLR-1023 exhibited promising protective efficacy against lethal IAV infection. Our findings discovered LYN and LYN-agonist as potential drug candidates targeting IAV NP, which will facilitate the development of host-directed antiviral therapies.

  • Open Access

    Enolase 1 suppresses influenza A virus replication by blocking the nuclear import of the viral ribonucleoprotein complex

    by Xingtian Kong, Junwen Liu, Qiyun Zhu, Shuai Xu

    Influenza A viruses (IAVs) pose a severe threat to humans and animals, and rely on numerous proviral host proteins to support their replication. Nevertheless, multiple host factors exert restrictive effects on the IAV life cycle through different mechanisms. Enolase 1 (ENO1), a glycolytic enzyme, has been identified to affect viral replication of limited viruses; and its role in the IAV life cycle remains poorly understood. In this study, we found that ENO1 is a negative regulator of IAV replication. Knockdown of ENO1 significantly enhanced IAV propagation, whereas its overexpression dramatically reduced viral growth. Further, ENO1 reduced IAV replication independent of the glycolysis pathway. ENO1 interacted with viral nucleoprotein (NP) and attenuated viral polymerase activity through blocking the nuclear import of the viral ribonucleoprotein (vRNP) complex. Mechanistically, ENO1 impaired the binding of NP to importin α3, but not to importin α1, α5, or α7, thereby preventing the nuclear import of the vRNP complex and suppressing IAV replication. Taken together, our study uncovered a novel function of ENO1 in IAV replication, and shed new light on understanding virus-host interactions. Our findings indicated that ENO1 may be a promising target for the development of antiviral drugs.


  • Open Access

    The viral proteins of influenza A virus competitively bind to TRIM31 with MAVS to fine-tune the antiviral innate immunity

    by Jiaxin Huang, Shuai Xu, Junwen Liu, Qian Wang, Lu Han, Mengyao Ji, Caoqi Lei, Qiyun Zhu, Hualan Chen

    The influenza A virus (IAV) continues to pose a serious threat to animals and humans, making it urgent to reveal more about IAV-host interactions. Tripartite motif protein 31 (TRIM31), an E3 ubiquitin ligase, has been identified as an agonist of the type-I interferon (IFN-I) response against RNA viruses by targeting mitochondrial antiviral signaling protein (MAVS). Here, we demonstrated that TRIM31 plays critical and novel roles in the life cycle of IAV. TRIM31 promoted the IFN-I signaling induced by IAV; however, it was surprisingly found that TRIM31 does not affect IAV replication. Instead, IAV replication was significantly promoted by TRIM31 in MAVS- or interferon receptor-deficient cells, suggesting TRIM31 may facilitate IAV replication in an interferon-independent manner. Mechanistically, TRIM31 interacted specifically with the basic polymerase 1 (PB1), acidic polymerase (PA), and hemagglutinin (HA) proteins of different subtypes of IAV. The interaction between TRIM31 and the PB1, PA, and HA proteins enhances the stability and polymerase and membrane fusion activities of these viral proteins by catalyzing the K63-linked ubiquitination. Further, the PB1, PA, and HA proteins competitively bind to TRIM31 for IAV replication, leading to the attenuation of the TRIM31-MVAS complex-mediated IFN-I signaling activation. Therefore, the antiviral and proviral effects of TRIM31 reach a balance in IAV-infected cells, resulting in no significant impact on IAV replication. Our novel findings revealed an IAV-specific mechanism that IAV exploits TRIM31 to fine-tune the antiviral innate response and maintain the homeostasis of viral replication. IMPORTANCE: During the long-term symbiosis with the host, IAVs have evolved a series of unique mechanisms to adapt to the host and support their own replication. The MAVS-mediated IFN-I signaling pathway is crucial for host cells to defend against RNA virus invasion, with TRIM31 functioning as a specific agonist for the activation of IFN-I antiviral response. In the present study, we demonstrated that IAV exploits TRIM31 to promote the stability and activity of viral proteins and reduces the positive effect of TRIM31 on the IFN-I response, thereby preventing TRIM31 from inhibiting IAV replication. Therefore, our results revealed a novel mechanism employed by IAV to adapt to host antiviral response and expanded our understanding of virus–host interactions.